Disc Medicine, Inc. Restructuring Costs
Disc Medicine, Inc. (IRON) reported Restructuring Costs of $1.70 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2022-11-10
- Disc Medicine, Inc. restructuring costs for the quarter ending 2022-09-30 was $0.00.
- Disc Medicine, Inc. restructuring costs for the quarter ending 2022-06-30 was $1.70M.
- Disc Medicine, Inc. restructuring costs for the quarter ending 2022-03-31 was $1.70M.
- Disc Medicine, Inc. restructuring costs for fiscal 2021 was $1.40M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.70M derived: sum of 2 quarters · filed 2022-11-10 | $1.70M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $1.70M 10-Q · filed 2022-08-11 | $1.70M 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $1.70M 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | $1.40M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |